Please login to the form below

Not currently logged in
Email:
Password:

Sanofi enters vaccines partnership with Sutro

Will develop products for two undisclosed targets

Sanofi Pasteur

Sanofi and Sutro Biopharma have agreed a deal to develop two vaccines for as-yet undisclosed targets.

The collaboration will grant Sanofi's vaccines division Sanofi Pasteur access to Sutro's cell-free protein synthesis technology to research protein-based vaccines.

Specifics terms of the deal were not divulged, although Sutro's current research efforts mainly involve therapeutics in the field of oncology, including the development of antibody-drug conjugates.

Sanofi Pasteur's vaccines currently cover 20 infectious diseases, including tuberculosis, cholera, influenza and hepatitis, and it is currently investigating a product to protect against the dengue virus.

"This collaboration highlights the potential value of Sutro's biochemical synthesis technology for the production of vaccines and provides additional validation of the benefits of our technology platform," said William Newell, CEO of San Francisco-based Sutro.

"We are looking forward to expanding our expertise in protein expression into the field of vaccines with an established leader in the area."

The deal is the second major collaboration Sutro has agreed in recent months following an agreement with Celgene that could be worth up to $500m to develop novel antibody-drug conjugates bispecific antibodies for two undisclosed targets

Both deals followed two major research appointments made by the company in October, 2012.

Dr Jeremy Bender joined from Allos as chief business officer, while Dr Aaron Sato joined from OncoMed Pharmaceuticals as VP, research.

Both have significant experience in leading partnerships between businesses, and they appear to have influenced Sutro's recent collaborations.

At the time, the company's CEO William Newell said: “These appointments reflect an important step in the growth of our company as we continue to advance our novel, cell-free approach to designing, developing and manufacturing next-generation cancer therapeutics.”

7th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics